Blog

Babson Diagnostics Raises $31 Million in Series B Funding to Drive Retailization of Customer-First, Convenient, and Highly Accessible Diagnostic Blood Testing

– Babson Diagnostics announced a $31m Series B financing round. – The round was led by Emerald Development Managers with participation from Siemens Healthineers, Prism Ventures, and Lago Consulting Group. – Babson Diagnostics is a transformative medical technology company improving customer access to diagnostic blood testing. – Babson intends to use the Series B funding to expand its laboratory and ecosystem infrastructure, finalize its blood testing solution development, and grow its sales and marketing teams. – Neil Cohen, founder and chairman of Emerald Development Managers, will join the company’s board of directors.